Matsumoto Koutarou, Maeda Megumi, Matsuo Ryu, Fukuda Haruhisa, Ago Tetsuro, Kitazono Takanari, Kamouchi Masahiro, Irie Fumi
Department of Health Care Administration and Management, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Center for Cohort Studies, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Glob Health Med. 2025 Jun 30;7(3):233-240. doi: 10.35772/ghm.2025.01053.
This study aimed to determine whether procedure volume is associated with 30-day mortality following endovascular thrombectomy (EVT) or intravenous recombinant tissue plasminogen activator (IV rt-PA) for stroke during the introduction period of EVT in Japan. Using nationwide claims records, we investigated data from 8,227 patients undergoing EVT and 13,406 and 6,035 patients undergoing rt-PA monotherapy in hospitals with and without EVT capability, respectively, between April 2014 and February 2016 in Japan. Procedure volume was categorized into three groups according to tertiles of the annual number of EVTs or IV rt-PA injections performed in the hospitals. Hierarchical logistic regression demonstrated that the odds ratio (95% confidence interval) of 30-day mortality following EVT was significantly lower in middle- (0.77 [0.62-0.96]) and high- (0.69 [0.53-0.89]) volume hospitals than that in low-volume hospitals even after adjusting for potential confounding factors. The generalized additive mixed models revealed no obvious threshold volume of EVT to reduce the mortality risk. By contrast, mortality risk following IV rt-PA monotherapy did not decrease in hospitals without EVT capability but did with increasing IV rt-PA volume in hospitals with EVT capability (P for heterogeneity 0.003). The risk of 30-day mortality after EVT for acute ischemic stroke decreased linearly according to EVT procedure volume in each hospital. However, the association between IV rt- PA volume and mortality risk was modified by the hospital's EVT capability. Further research is warranted to determine whether the volume-outcome relationship we observed is a temporary phenomenon following EVT or a consistent trend over time.
本研究旨在确定在日本血管内血栓切除术(EVT)引入期,手术量是否与EVT或静脉注射重组组织型纤溶酶原激活剂(IV rt-PA)治疗卒中后的30天死亡率相关。利用全国范围内的理赔记录,我们调查了2014年4月至2016年2月期间日本有和没有EVT治疗能力的医院中,8227例接受EVT治疗的患者以及分别13406例和6035例接受rt-PA单药治疗的患者的数据。根据医院每年进行的EVT或IV rt-PA注射次数的三分位数,将手术量分为三组。分层逻辑回归表明,即使在调整潜在混杂因素后,中等手术量(0.77[0.62-0.96])和高手术量(0.69[0.53-0.89])医院中EVT后30天死亡率的比值比(95%置信区间)显著低于低手术量医院。广义相加混合模型显示,没有明显的EVT阈值手术量来降低死亡风险。相比之下,在没有EVT治疗能力的医院中,IV rt-PA单药治疗后的死亡风险没有降低,但在有EVT治疗能力的医院中,随着IV rt-PA量的增加而降低(异质性P值为0.003)。急性缺血性卒中EVT后30天死亡率风险在各医院中根据EVT手术量呈线性下降。然而,IV rt-PA量与死亡风险之间的关联因医院的EVT治疗能力而改变。有必要进行进一步研究,以确定我们观察到的手术量-结局关系是EVT后的暂时现象还是随时间的一致趋势。